Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback